Chataway, J, De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, Macmanus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Giovannoni, G, Gandini Wheeler-kingshott, C A, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J & Stallard, N & Chandran, S 2020, ' Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART) : a phase 2b, multiarm, double-blind, randomised placebo-controlled trial ', The Lancet Neurology, vol. 19, no. 3, pp. 214-225 . https://doi.org/10.1016/S1474-4422(19)30485-5 O2, repositorio institucional de la UOC Universitat Oberta de Catalunya (UOC) Chataway, J, De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, MacManus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Giovannoni, G, Gandini Wheeler-Kingshott, C A, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J, Stallard, N, Chandran, S & MS-SMART Investigators 2020, ' Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART) : a phase 2b, multiarm, double-blind, randomised placebo-controlled trial ', The Lancet Neurology, vol. 19, no. 3, pp. 214-225 . https://doi.org/10.1016/S1474-4422(19)30485-5 The Lancet Neurology, 19(3), 214-225. Lancet Publishing Group
De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, Macmanus, D, Prados, F, Marshall, I, Solanky, B, Samson, R S, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Gnanapavan, S, Giovannoni, G, Wheeler-kingshott, C A G, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J, Stallard, N, Chandran, S & Chataway, J 2020, ' Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT ', Efficacy and Mechanism Evaluation, vol. 7, no. 3, pp. 1-72 . https://doi.org/10.3310/eme07030 Efficacy and Mechanism Evaluation, Vol 7, Iss 3 (2020)